Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 2/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2187234 | 0.86 | NPBWR1 (0.49) | NPBWR1MCHR1SMN1; SMN2PDE1APDE1B | |
| SCHEMBL2551079 | 0.82 | PDE1A (0.46) | NPBWR1MCHR1SMN1; SMN2PDE1APDE1B | |
| SCHEMBL2186059 | 0.82 | PDE1A (0.46) | NPBWR1MCHR1SMN1; SMN2PDE1APDE1B | |
| SCHEMBL2545681 | 0.78 | L3MBTL1 (0.57) | NPBWR1SMN1; SMN2PDE1APDE1BPDE1C | |
| SCHEMBL2551062 | 0.78 | NPBWR1 (0.77) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL14844510 | 0.76 | NPBWR1 (0.67) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL24763741 | 0.74 | NPBWR1 (0.54) | NPBWR1MCHR1SMN1; SMN2PDE1APDE1B | |
| SCHEMBL14844531 | 0.73 | NPBWR1 (0.84) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL27077877 | 0.73 | NPBWR1 (0.66) | NPBWR1MCHR1SMN1; SMN2 | |
| SCHEMBL24251307 | 0.72 | NPBWR1 (0.68) | NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | NPBWR1 1079/4885MCHR1 687/4885SMN1; SMN2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.